Annexon, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ANNX Nasdaq 2836 www.annexonbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Annexon, Inc.

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Apr 16th, 2025 8:05 pm
Why Annexon Inc. (ANNX) Went Down On Thursday? - Apr 10th, 2025 1:24 pm
Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder - Apr 9th, 2025 7:20 pm
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting - Apr 8th, 2025 8:05 pm
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting - Apr 3rd, 2025 10:18 pm
Here's Why We're Not Too Worried About Annexon's (NASDAQ:ANNX) Cash Burn Situation - Mar 31st, 2025 1:07 pm
Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks - Mar 16th, 2025 10:05 am
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones - Mar 3rd, 2025 1:00 pm
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference - Feb 26th, 2025 9:05 pm
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Feb 18th, 2025 1:00 pm
Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting - Feb 13th, 2025 1:30 pm
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year - Jan 13th, 2025 1:00 pm
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones - Jan 10th, 2025 1:00 pm
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 7th, 2025 1:00 pm
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS) - Dec 16th, 2024 12:30 pm
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting - Dec 5th, 2024 1:00 pm
The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate. - Nov 19th, 2024 8:00 am
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones - Nov 14th, 2024 1:00 pm
Annexon Biosciences to Present at the Jefferies London Healthcare Conference - Nov 13th, 2024 9:05 pm
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting - Oct 22nd, 2024 12:00 am